Stocks and Investing
Stocks and Investing
Tue, April 20, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, April 19, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
David Lewis Maintained (BVS) at Buy with Increased Target to $19 on, Apr 19th, 2021
David Lewis of Morgan Stanley, Maintained "Bioventus Inc." (BVS) at Buy with Increased Target from $18 to $19 on, Apr 19th, 2021.
David has made no other calls on BVS in the last 4 months.
There are 3 other peers that have a rating on BVS. Out of the 3 peers that are also analyzing BVS, 0 agree with David's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with David
- Amit Hazan of "Goldman Sachs" Initiated at Strong Buy and Held Target at $19 on, Monday, March 8th, 2021
- Kyle Rose of "Canaccord Genuity" Initiated at Strong Buy and Held Target at $23 on, Monday, March 8th, 2021
- Robbie Marcus of "JP Morgan" Initiated at Buy and Held Target at $17 on, Monday, March 8th, 2021
Contributing Sources